Anti-inflammatory properties of 5-hydroxypirimidine derivatives on the model of CFA-induced paw and ankle joint edema in rats
https://doi.org/10.37489/2587-7836-2022-3-33-36
Abstract
Anti-inflammatory potency of 5-hydroxypyrimidine derivatives SNK-411 (2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) and SNK-578 (hydrochloride 2-isobutyl-4,6-dimethyl-5-hydroxypirimidine) was evaluated on the model of complete Freund`s adjuvant (CFA)-induced exudative inflammation in experiment on 60 outbreed male rats weighing 180–200 g in comparison with prednisolone. Prednisolone, SNK-411 and SNK-578 were injected twice: in 24 and 2 hours in before the injection of CFA. Prednisolone was administered in dose of 10 mg/kg, SNK-411 in doses of 25 mg/kg and 40 mg/kg, SNK-578 in doses of 10 mg/kg and 25 mg/kg. Paw and ankle joint edema were registered 24 hours after subplantar injection of CFA in right hind foot. Prednisolone administration in dose of 10 mg/kg decreased paw and ankle joint edema, SNK-578 in dose of 25 mg/kg decreased exudative edema of the paw, SNK-411 in dose of 40 mg/kg decreased paw and ankle joint edema. Acquired data correlates with previously obtained results that 5-hydroxypirimidine derivatives have antiallergenic effect on the model of systemic anaphylaxis in experiment on guinea pigs.
Supporting agencies: Theworkwas carried outwithin the framework of State task № ЕГИСУ 122020100334-2.
About the Authors
R. V. Zhurikov
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Zhurikov Ruslan V. Junior researcher of laboratory of drug toxicology
SPIN code: 6648-1794
Moscow
L. P. Kovalenko
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Kovalenko Larisa P. Dr. Sci. Biological, Leading researcher of laboratory of drug toxicology
SPIN code: 5185-4250
Moscow
S. V. Nikitin
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Nikitin Sergey V. PhD, Cand. Sci. (Chemical), Senior researcher of laboratory of drug toxicology
Moscow
References
1. Belska NV, Danilets MG, Belsky YP, et al. Modelling of an anaphylaxis using BALb/c mice. Biomedicine. 2010; 1(1):37–50 (In Russ).
2. Kuzubova N.A., Titova O.N. T2-associated diseases: focus on the comorbid patient. Meditsinskiy sovet = Medical Council. 2020;(17):57–64. (In Russ). DOI: 10.21518/2079-701X-2020-17-57-64
3. Kovalenko LP, Korzhova KV, Nikitin SV. Antiallergic and anti-inflammatory activity of 5-oxypyrimidine derivatives (SNK-411 and SNK-578). Experimental and clinical pharmacology. 2020;83(10):9–12. (In Russ.). DOI: 10.30906/0869-2092-2020-83-10-9-12
4. Uteshev DB. Metodicheskie rekomendatsii po doklinicheskomu izucheniyu lekarstvennih stredstv dlya lecheniya bronhialnoi astmi i hronicheskoy obstruktivnoi bolezni legkih. Rukovodstvo po provedeniyu issledovaniy lekarstvennih sredstv. Ed by Mironov AN. Moscow: Grif I K; 2012. (In Russ).
5. Douwes J, Gibson P, Pekkanen J, Pearse N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002;57(7):643–648. DOI: 10.1136/thorax.57.7.643.
Review
For citations:
Zhurikov R.V., Kovalenko L.P., Nikitin S.V. Anti-inflammatory properties of 5-hydroxypirimidine derivatives on the model of CFA-induced paw and ankle joint edema in rats. Pharmacokinetics and Pharmacodynamics. 2022;(3):33-36. (In Russ.) https://doi.org/10.37489/2587-7836-2022-3-33-36
Views:
365
Email this article 